Literature DB >> 24810926

Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p.

Carlos Marino Cabral Calvano Filho1, Daniele Carvalho Calvano-Mendes, Kátia Cândido Carvalho, Gustavo Arantes Maciel, Marcos Desidério Ricci, Ana Paula Torres, José Roberto Filassi, Edmund Chada Baracat.   

Abstract

New concepts in epigenetics, microRNAs, and gene expression analysis have significantly enhanced knowledge of cancer pathogenesis over the last decade. MicroRNAs (miRNAs) are a class of non-coding RNAs that regulate gene expression by base pairing with target messenger RNAs (mRNAs), resulting in the repression of translation or the degradation of mRNA. To compare the carcinogenic process in tumors with different prognoses, we used real-time RT-PCR to evaluate the miRNA expression profiles of 24 triple-negative breast invasive ductal carcinoma, 20 luminal A breast invasive ductal carcinoma, and 13 normal breast parenchyma controls. We extracted total RNA from tissues fixed in formol and embedded in paraffin (FFPE). Results revealed the upregulation of miR-96-5p (9.35-fold; p = 0.000115), miR-182-5p (7.75-fold; p = 0.000033), miR-7-5p (6.71-fold; p = 0.015626), and miR-21-5p (6.10-fold; p = 0.000000) in tumors group. In addition, the expression of miR-125b-5p (4.49-fold; p = 0.000000) and miR-205-5p (4.36-fold; p = 0.006098) was downregulated. When the expression profiles of triple-negative and luminal A tumors were compared, there was enhanced expression of miR-17-5p (4.27-fold; p = 0.000664), miR-18a-5p (9.68-fold; p = 0.000545), and miR-20a-5 (4.07-fold; p = 0.001487) in the triple-negative tumors compared with luminal A. These data suggest that there is a similar regulation of certain miRNAs in triple-negative and luminal A tumors. However, it is possible that differences in the expression of miR-17-92 cluster will explain the phenotypic differences between these molecular tumor subtypes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24810926     DOI: 10.1007/s13277-014-2025-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  43 in total

1.  MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function.

Authors:  David T Humphreys; Belinda J Westman; David I K Martin; Thomas Preiss
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-15       Impact factor: 11.205

2.  Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer.

Authors:  Nobuyasu Yoshimoto; Tatsuya Toyama; Satoru Takahashi; Hiroshi Sugiura; Yumi Endo; Mai Iwasa; Yoshitaka Fujii; Hiroko Yamashita
Journal:  Breast Cancer Res Treat       Date:  2011-07-14       Impact factor: 4.872

3.  MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression.

Authors:  Ming Zhou; Zixing Liu; Yuhua Zhao; Yan Ding; Hao Liu; Yaguang Xi; Wei Xiong; Guiyuan Li; Jianrong Lu; Oystein Fodstad; Adam I Riker; Ming Tan
Journal:  J Biol Chem       Date:  2010-05-11       Impact factor: 5.157

4.  Human let-7a miRNA blocks protein production on actively translating polyribosomes.

Authors:  Stephanie Nottrott; Martin J Simard; Joel D Richter
Journal:  Nat Struct Mol Biol       Date:  2006-11-26       Impact factor: 15.369

5.  High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis.

Authors:  Liu Hong; Jianjun Yang; Yu Han; Qun Lu; Jun Cao; Labiq Syed
Journal:  Gene       Date:  2012-07-25       Impact factor: 3.688

6.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

7.  MicroRNA-182-5p targets a network of genes involved in DNA repair.

Authors:  Keerthana Krishnan; Anita L Steptoe; Hilary C Martin; Shivangi Wani; Katia Nones; Nic Waddell; Mythily Mariasegaram; Peter T Simpson; Sunil R Lakhani; Brian Gabrielli; Alexander Vlassov; Nicole Cloonan; Sean M Grimmond
Journal:  RNA       Date:  2012-12-18       Impact factor: 4.942

Review 8.  [The roles of miR-17-92 cluster in mammal development and tumorigenesis].

Authors:  Zhen-Wu ZHANG; Yang AN; Chun-Bo TENG
Journal:  Yi Chuan       Date:  2009-11

Review 9.  Triple-negative breast cancer: new perspectives for novel therapies.

Authors:  Yashin A Mahamodhossen; Wei Liu; Zhou Rong-Rong
Journal:  Med Oncol       Date:  2013-07-04       Impact factor: 3.738

10.  A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation.

Authors:  Zuoren Yu; Chenguang Wang; Min Wang; Zhiping Li; Mathew C Casimiro; Manran Liu; Kongming Wu; James Whittle; Xiaoming Ju; Terry Hyslop; Peter McCue; Richard G Pestell
Journal:  J Cell Biol       Date:  2008-08-11       Impact factor: 10.539

View more
  48 in total

1.  miR-148a and miR-17-5p synergistically regulate milk TAG synthesis via PPARGC1A and PPARA in goat mammary epithelial cells.

Authors:  Zhi Chen; Jun Luo; Shuang Sun; Duoyao Cao; Huaiping Shi; Juan J Loor
Journal:  RNA Biol       Date:  2017-01-17       Impact factor: 4.652

2.  Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands.

Authors:  Orsolya Kiss; Anna-Mária Tőkés; Semir Vranic; Zoran Gatalica; László Vass; Nóra Udvarhelyi; A Marcell Szász; Janina Kulka
Journal:  Virchows Arch       Date:  2015-08-21       Impact factor: 4.064

3.  Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy.

Authors:  Ginés Luengo-Gil; Elena García-Martínez; Asunción Chaves-Benito; Pablo Conesa-Zamora; Esther Navarro-Manzano; Enrique González-Billalabeitia; Elisa García-Garre; Alberto Martínez-Carrasco; Vicente Vicente; Francisco Ayala de la Peña
Journal:  Cell Oncol (Dordr)       Date:  2019-05-21       Impact factor: 6.730

4.  Gastric cardia adenocarcinoma microRNA profiling in Chinese patients.

Authors:  Shegan Gao; Fuyou Zhou; Chen Zhao; Zhikun Ma; Ruinuo Jia; Shuo Liang; Mengxi Zhang; Xiaojuan Zhu; Pengfei Zhang; Lu Wang; Feng Su; Jiangman Zhao; Gang Liu; Bo Peng; Xiaoshan Feng
Journal:  Tumour Biol       Date:  2016-01-18

5.  MicroRNAs and Heat Shock Proteins in Breast Cancer Biology.

Authors:  Mehmet Taha Yildiz; Lütfi Tutar; Nazlı Irmak Giritlioğlu; Banu Bayram; Yusuf Tutar
Journal:  Methods Mol Biol       Date:  2022

6.  High-Intensity Interval Training Improves Cardiac Function by miR-206 Dependent HSP60 Induction in Diabetic Rats.

Authors:  Maryam Delfan; Raheleh Amadeh Juybari; Sattar Gorgani-Firuzjaee; Jens Høiriis Nielsen; Neda Delfan; Ismail Laher; Ayoub Saeidi; Urs Granacher; Hassane Zouhal
Journal:  Front Cardiovasc Med       Date:  2022-06-29

7.  MTUS1 and its targeting miRNAs in colorectal carcinoma: significant associations.

Authors:  Onder Ozcan; Murat Kara; Onder Yumrutas; Esra Bozgeyik; Ibrahim Bozgeyik; Ozgur Ilhan Celik
Journal:  Tumour Biol       Date:  2015-12-07

8.  MiR-135 post-transcriptionally regulates FOXO1 expression and promotes cell proliferation in human malignant melanoma cells.

Authors:  Jian-Wen Ren; Zhang-Jun Li; Chen Tu
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

9.  miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.

Authors:  Brian D Adams; Vikram B Wali; Christopher J Cheng; Sachi Inukai; Carmen J Booth; Seema Agarwal; David L Rimm; Balázs Győrffy; Libero Santarpia; Lajos Pusztai; W Mark Saltzman; Frank J Slack
Journal:  Cancer Res       Date:  2015-12-16       Impact factor: 12.701

10.  MiR130b-Regulation of PPARγ Coactivator- 1α Suppresses Fat Metabolism in Goat Mammary Epithelial Cells.

Authors:  Zhi Chen; Jun Luo; LiuAn Ma; Hui Wang; WenTing Cao; HuiFei Xu; JiangJiang Zhu; YuTing Sun; Jun Li; DaWei Yao; Kang Kang; Deming Gou
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.